

Bluedot Organics

Portfolio Specs Sheets



CBD VARIETIES

Remidi #1

Highly standardized flower

CBD (CAS 13956-29): 14.5% ± 2.5 (12% - 17%)

THC (CAS 1972-08-3): ≤0.9%



Terpene (mg/kg) : β-Myrcene, 520 ; α-Pinene, 138 ; β-Caryophyllene, 69.1 ; β-Pinene, 58.4 ; Limonene, 45.9 ; Guaiol, 35.0 ; α-Humulene, 21.5 ; α-Bisabolol, 18.1 ; Linalool, 8.97

Predominat terpenes

β-Myrcene	Earthy and musky scent
α-Pinene	Fresh pine scent
β-Caryophyllene	Woody/Spicy smell of cloves/pepper



Resolution
ICA 18404 (Plena™)



Main therapeutic effect

Pain (inflammation and physical trauma)

Description and therapeutic effect

The genetics that gives life to Remidi #1 is expressed in a tall and elongated architecture producing a large number of buds. Remidi #1 stands out for being a variety with a high CBD content and a low THC level of less than 1.0%.

Its high CBD content together with its consistent terpene profile, highlighting the dominance of β-Myrcene, has allowed to establish through scientific studies the high medicinal potential of Remidi #1, having the potential to induce therapeutic effects that leads to treat medical conditions caused by inflammatory processes (e.g. general pain, pain caused by physical trauma, etc.). The anti-inflammatory properties of both CBD and terpenes (β-Myrcene, β-Caryophyllene, limonene, α-Humulene, α-Bisabolol y Linalool) have allowed us to advance our research in the development of effective formulations for the treatment of this condition (pain) by taking advantage of the synergistic process between the components of Remidi #1 flower.



Remidi #2

Highly standardized flower

CBD (CAS 13956-29): 13.8% ± 1.8 (12% - 15.6%)

THC (CAS 1972-08-3): ≤0.9%



Terpene (mg/kg): β-Myrcene, 320 ; α-Bisabolol, 94.5 ; β-Caryophyllene, 76.4 ; Guaiol, 74.1 ; Limonene, 56.4 ; α-Humulene, 23.7 ; β-Pinene, 20.5 ; Linalool, 18.5 ; α-Pinene, 14.1 ; Eucalyptol, 6.52

Predominat terpenes

β-Myrcene	Earthy and musky scent
α-Bisabolol	Nutty, fruity scent with herbal and floral undertones
β-Caryophyllene	Woody/Spicy smell of cloves/pepper



Resolution
ICA 18407 (Plena™)



Main therapeutic effect

Pain (inflammation and physical trauma) ;
Neurological (ADHD, Epilepsy, Schizophrenia)

Description and therapeutic effect

Current studies have shown that CBD is a bioactive compound with therapeutic potential for the treatment of diseases derived from neuroinflammatory processes (e.g. epilepsy, anxiety, schizophrenia, ADHD, etc). Pre-clinical and clinical data show an overall increase in efficiency in the therapeutic effect derived from the synergy between phytocannabinoids and terpenes, when administered together they are more effective in improving neuropathic pain than the use of a single compound. Remidi #2 is a variety rich in CBD as well as β-Myrcene, α-Bisabolol y β-Caryophyllene, terpenes widely studied for their anti-inflammatory, anticonvulsant and antipsychotic properties, respectively. Our flower, Remidi #2, has been highly standardized in order to produce unique and consistent profiles of phytocannabinoids as well as terpenes so that the ratio between its main components can generate an efficient therapeutic effect in the treatment of physical pain related conditions such as pain from neuropathic conditions.



THC VARIETIES

Remidi #3

Highly standardized flower

THC (CAS 1972-08-3): 21% ± 0.9 (20.1% - 21.9%)

CBD (CAS 13956-29): ≤0.1%7



Terpene (mg/kg): β-Myrcene, 112 ;
β-Caryophyllene, 54.4 ; Limonene, 36.1 ;
α-Humulene, 24.3 ; Linalool, 24.6 ; β-Pinene, 17.4 ;
α-Pinene, 10.9 ; Terpinolene, 7.57

Predominat terpenes

β-Myrcene	Earthy and musky scent
β-Caryophyllene	Woody/Spicy smell of cloves/pepper
Limonene	Fresh, light, sweet citrus fruit scent



Resolution
ICA 069435 (Plena™)



Main therapeutic effect

Pain (inflammation and physical trauma) ;
Mood (Anxiety, depression, PTSD)

Description and therapeutic effect

The Remidi #3 flower is characterized by being compact and producing high concentrations of THC and terpenes β-Myrcene, β-Caryophyllene y Limonene. In humans, THC has been shown to have efficacy in reducing depression and anxiety in co-administration with CBD. THC activates the endocannabinoid receptors CB1 and CB2 which are found in the nerve and immune cells, respectively. This activation together with the combination in the same formulation (plant) of the terpenes β-Myrcene and limonene, synergistically produce an effect similar to that of antidepressants through interaction with the monoaminergic system. Remidi #3 has a standardized profile in terms of THC - terpenes ratio, standing out for its anxiolytic and antidepressant properties of these components as well as its anti-inflammatory properties leading to its use for the treatment of pain-related conditions.



Remidi #4

Highly standardized flower

THC (CAS 1972-08-3): 23.7% ± 1.9 (21.8% - 25.6%)

CBD (CAS 13956-29): ≤0.05%


Terpene (mg/kg): Terpinolene, 169 ; β-Myrcene, 83.9 ; β-Pinene, 80.6 ; Ocimene, 75.2 ; α-Pinene, 66.9 ; Limonene, 50.0 ; δ-3-Carene, 18.1 ; α-Terpinene, 16.1 ; Linalool, 14.3

Predominant terpenes


Terpinolene	Fresh pine scent blended with floral notes and a hint of citrus
β-Myrcene	Earthy and musky scent
α-Pinene	Fresh pine scent



Resolution
ICA 069440 (Plena™)



Concentration (terpene based %)



Main therapeutic effect

Pain (inflammation and physical trauma) ;
Energy (Focus, Creativity, Sports & Exercise)

Description and therapeutic effect

Remidi #4 is our flower with the highest THC content (approx. 26%) and low CBD levels of less than 1.0%. Remidi #4 flowers are compact with a large dominance of terpinolene, β-Myrcene, β-Pinene and Ocimene which gives it a fresh pine aroma as well as citrus notes. It is well known that THC is a partial agonist of the CB1 receptor and of the CB2 receptor analogous to anandamide, and underlying many of its activities as a psychoactive agent, analgesic, muscle relaxant and antispasmodic. In addition, it is a bronchodilator, antioxidant, neuroprotective and has 20 times the anti-inflammatory power of aspirin and twice that of hydrocortisone. The high terpinolene content in Remidi #4 gives it anti-inflammatory and analgesic characteristics for the treatment of pain-related conditions. The synergy between limonene, pinene and linalool with THC has proven to have a high therapeutic value for the treatment of diseases such as Alzheimer's disease, leading to an improvement in the processes of memory, concentration, as well as stimulating creativity processes in low doses.



Remidi #5

Highly standardized flower


THC (CAS 1972-08-3): 21.8% ± 0.9 (20.9% - 22.7%)

CBD (CAS 13956-29): ≤0.05%

Terpene (mg/kg): Limonene, 86.4 ; β-Caryophyllene, 68.2 ; Linalool, 64.9 ; β-Myrcene, 48.6 ; β-Pinene, 36.9 ; α-Pinene, 25.2 ; α-Humulene, 22.0 ; Terpinolene, 8.48 ; Camphene, 7.39 ; Nerolidol 1, 4.48 ; α-Bisabolol, 3.07

Predominat terpenes

Limonene	Fresh, light, sweet citrus fruit scent
β-Caryophyllene	Woody/Spicy smell of cloves/pepper
Linalool	Floral, lavender scent




Resolution
ICA 069442 (Plena™)


Main therapeutic effect

Pain (inflammation and physical trauma) ; Mood (Anxiety, depression, PTSD) ; Stress, muscle tension and sleep

Description and therapeutic effect

Remidi #5 flowers are characterized by being compact and highly resinous with a strong citrus aroma with notes of lavender and fresh pine. The strong expression of the terpenes, β-Caryophyllene, linalool y β-Myrcene in Remidi #5, can not only induce a therapeutic effect for pain control or regulate affectations in mental well-being caused by conditions such as depression and/or anxiety, but also help to control symptoms related to stress, muscle tension and sleep-related problems such as insomnia. The synergy created between Remidi #5's major terpenes and its high THC content could potentially increase the efficiency of the therapeutic effect by increasing the bioavailability of Remidi #5's main cannabinoid.





pg
07



BLUEDOT
ORGANICS



Click to see more
detailed pictures

Cultivation by Plena Global

Nemocón, Cundinamarca,
COLOMBIA.

Control Union CUMCS GACP
v 4.0 Certified.

Prices: for discussion.

Lead time: 180 days* from the
production request date.

Contact us to attend your
questions and requests:

Christian Gil +573105030329
cgil@bluedotorganics.com
www.bluedotorganics.com



Christian Gil

*for the first order.